Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What CAGR Is Anticipated for the Hormone Refractory Prostate Cancer Market Through 2029?
The market size for hormone-refractory prostate cancer has seen a rapid expansion over the past years. The market is projected to grow from $7.35 billion in 2024 to $8.12 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.4%. The historical growth is linked to an escalated occurrence of prostate cancer, heightened PSA (prostate-specific antigen) screening, enhanced physician knowledge and specialization, the rise in the use of palliative care, and an increased number of clinical trials.
The market size of hormone-refractory prostate cancer is predicted to experience swift expansion in the coming years, escalating to a value of $11.91 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 10.1%. The projected growth across the specified period can be credited to factors such as the rising utilization of genetic biomarkers, the advancing adoption of precision medicine, the expansion of PARP inhibitors, the enhancement of worldwide access to HRPC treatments, and the increasing clinical use of combination regimens. Key trends expected across the forecast period encompass the increased use of combination therapies, developments in radiopharmaceuticals, the application of next-generation sequencing (NGS), the integration of digital tools and remote monitoring, and the production of next-generation androgen receptor inhibitors and PARP inhibitors specifically for HRPC.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25786&type=smp
What Market Forces Are Driving The Hormone Refractory Prostate Cancer Sector In 2025 And Beyond?
The expected rise in the hormone-refractory prostate cancer market can be attributed to increased investment in cancer research. This increased investment involves the allocation of funds and resources to further innovative methods for cancer detection, treatment, and prevention. With the global cancer burden on the rise, there is an urgent need for more effective and targeted treatment methods, driving this increase in investment. Such investments into research can lead to innovative treatments for hormone-refractory prostate cancer, including advanced therapies such as radioligand treatment and hormone inhibitors. It also provides funding for vital clinical trials and biomarker research, leading to more precise and effective outcomes. For example, in August 2024, the Cancer Research Institute (CRI), a nonprofit organization based in the US committed to pushing forward immunotherapy research, allocated around $22.8 million to fund 64 new grants dedicated to researchers from 42 institutions across seven countries in the fiscal year 2023-2024. As such, it can be concluded that the surge in cancer research investment is considerably enhancing the growth prospect of the hormone-refractory prostate cancer market.
How Is The Global Hormone Refractory Prostate Cancer Market Categorized By Segments?
The hormone refractory prostate cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin
2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy
5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)
What Long-Term Trends Are Likely To Affect The Hormone Refractory Prostate Cancer Market?
Leading firms in the hormone-refractory prostate cancer market are zeroing in on the creation of innovative therapies such as intravenous radioligand therapy. This method is a promising treatment aimed at increasing patient survival rates, especially in the case of drug-resistant disease forms. The therapy involves using radioactive molecules connected to ligands that can detect and bind to markers that are unique to cancer cells. This enables these therapy molecule complexes to eradicate cancerous cells from the inside while causing minimal damage to healthy cells in the vicinity. Taking an example from March 2025, Novartis AG, a pharmaceutical giant from Switzerland, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan). It gained authorization from the FDA and was conceived for the purpose of early intervention in patients afflicted by prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This cancer treatment is meant for patients who had previously undergone treatment with an androgen receptor pathway inhibitor (ARPI) and are deemed suitable for chemotherapy postponement. The broadened indication, which was based on the outcomes of the Phase III PSMAfore trial, tripled the number of eligible patients. It was proven that Pluvicto lessened the likelihood of radiographic progression or death by 59% and significantly prolonged the median radiographic progression-free survival relative to an ARPI adjustment. Significantly, Pluvicto stands out as the pioneering targeted radioligand therapy to be sanctioned for utilization prior to chemotherapy in this context, thereby presenting an alternative treatment avenue that both decelerates disease advancement and provides a favorable safety profile.
Which Firms Are Considered Leaders In The Hormone Refractory Prostate Cancer Market Space?
Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Ipsen Pharma, Exelixis Inc., Orion Corporation, Lantheus Holdings Inc., Clovis Oncology Inc., Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC
Get The Full Report Here:
What Role Do Regional Policies And Investments Play In Hormone Refractory Prostate Cancer Market Expansion?
North America was the largest region in the hormone-refractory prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25786&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
